Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children. [electronic resource]
Producer: 20100312Description: e7549 p. digitalISSN:- 1932-6203
- Antigens, Protozoan -- genetics
- Burkina Faso
- Child, Preschool
- Dose-Response Relationship, Drug
- Double-Blind Method
- Humans
- Infant
- Malaria -- prevention & control
- Malaria Vaccines -- therapeutic use
- Merozoites -- immunology
- Peptides -- chemistry
- Plasmodium falciparum -- metabolism
- Protozoan Proteins -- genetics
- Research Design
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.